Search keyWord :

LambdaTest unveils 2024 Partner of the Year Award winners

Feb 17, 2025

LambdaTest Partner Awards 2024 honors the top partners globally for their contributions to quality engineering and innovation.

Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases

Feb 17, 2025

BOSTON,Feb. 14,2025-- Bambusa Therapeutics,Inc. (Bambusa),a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders,today announced the successfu

A Global Leader! Huawei Cloud Stack Ranks No. 1 in Strategy and Execution of CloudOps Worldwide

Feb 17, 2025

SHENZHEN,China,Feb. 14,2025-- Omdia released the Omdia Universe: CloudOps,2025 report recently. In the report,Huawei was ranked No. 1 globally in CloudOps in terms of strategy and execution,and No. 2

Cloud4C Secures Dual AI Specializations on Microsoft Azure, Strengthening AI Capabilities

Feb 14, 2025

SINGAPORE,Feb. 13,2025-- Cloud4C,a global leader in AI-driven cloud and cybersecurity services,has achieved two prestigious AI specializations on Microsoft Azure: \'AI Platform on Microsoft Azure\' an

Aker Horizons ASA: Fourth-quarter results 2024

Feb 14, 2025

FORNEBU,Norway,Feb. 13,2025-- Aker Horizons ASA (OSE:AKH),a developer of green energy and industry,today announced results for the fourth quarter 2024. Aker Horizons\' net capital employed stood at NO

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003

Feb 14, 2025

SUZHOU,China,Feb. 13,2025-- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 bi

DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development

Feb 14, 2025

SEOUL,South Korea,Feb. 13,2025-- DAAN Biotherapeutics,a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies,has signed an exclusive licensing agreement w

Polyplastics Launches New Eco-friendly PLASTRON (R) ︎LFT with Reduced Weight, Higher Rigidity, and Strong Damping

Feb 14, 2025

TOKYO,Feb. 13,2025-- Polyplastics Co.,Ltd.,a global leader in engineering plastics,has launched PLASTRON (R) LFT (long fiber-reinforced thermoplastic) RA627P,an eco-friendly composite of polypropylene

Woolpert Welcomes Head of Strategic Growth, Asia-Pacific Susie Henderson

Feb 14, 2025

The accomplished global business executive will oversee the firm\'s strategic growth initiatives for the Asia-Pacific region.

Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa

Feb 14, 2025

The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial.

1 ... 272 273 274 275 276 277 278 ... 1271